Literature DB >> 1940481

Mycobacterium leprae-induced interferon-gamma production by household contacts of leprosy patients: association with the development of active disease.

E P Sampaio1, A L Moreira, G Kaplan, M F Alvim, N C Duppre, C F Miranda, E N Sarno.   

Abstract

Identification of individuals at risk for developing leprosy and their early diagnosis are central to effective disease control. Lack of immunologic response to Mycobacterium leprae among persons exposed to the infectious agent may be predictive of susceptibility. M. leprae-induced interferon-gamma (IFN-gamma) production by peripheral blood mononuclear cells was used as a measure of immune responsiveness. Household contacts of multibacillary patients likely to be at risk of developing active disease were identified, and a preliminary analysis after 2 years of follow-up is presented. A persistent in vitro negative response to M. leprae was present in 34.6% of the contacts, and a decrease in IFN-gamma production was noted in 52.5%. Five contacts (6.41%) developed leprosy during follow-up and, as predicted, belonged to the group of individuals who were negative or showed reduced levels of IFN-gamma in response to the antigen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940481     DOI: 10.1093/infdis/164.5.990

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Presence of human T-cell responses to the Mycobacterium leprae 45-kilodalton antigen reflects infection with or exposure to M. leprae.

Authors:  A Macfarlane; R Mondragon-Gonzalez; F Vega-Lopez; B Wieles; J de Pena; O Rodriguez; R Suarez y de la Torre; R R de Vries; T H Ottenhoff; H M Dockrell
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

3.  T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy.

Authors:  P Launois; R DeLeys; M N Niang; A Drowart; M Andrien; P Dierckx; J L Cartel; J L Sarthou; J P Van Vooren; K Huygen
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

4.  Human polymorphisms as clinical predictors in leprosy.

Authors:  Ernesto Prado Montes de Oca
Journal:  J Trop Med       Date:  2011-12-18

5.  Impact of PGL-I seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study.

Authors:  Nádia C Düppre; Luiz Antonio B Camacho; Anna M Sales; Ximena Illarramendi; José Augusto C Nery; Elizabeth P Sampaio; Euzenir N Sarno; Samira Bührer-Sékula
Journal:  PLoS Negl Trop Dis       Date:  2012-06-19

6.  Chemoprophylaxis of leprosy with rifampicin in contacts of multibacillary patients: study protocol for a randomized controlled trial.

Authors:  Daiane Santos Dos Santos; Nádia Cristina Duppre; Euzenir Nunes Sarno; Roberta Olmo Pinheiro; Anna Maria Sales; José Augusto Da Costa Nery; Milton Ozório Moraes; Luiz Antônio Bastos Camacho
Journal:  Trials       Date:  2018-04-23       Impact factor: 2.279

7.  Functional biomarker signatures of circulating T-cells and its association with distinct clinical status of leprosy patients and their respective household contacts.

Authors:  Pedro Henrique Ferreira Marçal; Rafael Silva Gama; Lorena Bruna Pereira de Oliveira; Olindo Assis Martins-Filho; Roberta Olmo Pinheiro; Euzenir Nunes Sarno; Milton Ozório Moraes; Lucia Alves de Oliveira Fraga
Journal:  Infect Dis Poverty       Date:  2020-12-20       Impact factor: 4.520

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.